Abivax (NASDAQ:ABVX) was given a new $140.00 price target on by analysts at Truist Financial Corporation.
Abivax (NASDAQ:ABVX) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Abivax (NASDAQ:ABVX) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
Abivax (NASDAQ:ABVX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
Abivax (NASDAQ:ABVX) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..